Lei Wang1, Ling Ma2, Xinli Wang3, Bing Li4, Shan Guo4, Qingdong Qiao3. 1. Department of Urology I, Xinxiang Central Hospital Xinxiang, Henan, China ; Department of Urology, Chinese PLA General Hospital, Medical School of Chinese PLA Beijing, China. 2. Department of Urology II, Xinxiang Central Hospital Xinxiang, Henan, China. 3. Department of Urology I, Xinxiang Central Hospital Xinxiang, Henan, China. 4. Department of Inspection, Xinxiang Central Hospital Xinxiang, Henan, China.
Abstract
BACKGROUND: Early prostate cancer antigen 2 (EPCA-2), a kind of nuclear matrix protein, may relate to prostate cancer. However, the association of EPCA-2 level in serum with prostate diseases has not been clarified in Chinese Han population. METHODS: EPCA-2 and prostate-specific antigen (PSA) levels in serum were detected by enzyme linked immunosorbent assay in 116 patients with prostate cancer (PCa), 342 patients with benign prostatic hyperplasia (BPH), and 174 healthy controls (Control) in Chinese population. Associations of serum EPCA-2 and PSA level with prostate diseases were analyzed by ANOVA. Comparison of diagnostic effect for prostate cancer between EPCA-2 and PSA was evaluated by Receiver Operator Curve, Chi-square test, and others. RESULTS: Serum EPCA-2 and PSA levels in PCa group were significantly higher than BPH and Control group (EPCA-2: F=200.05, P<0.01; PSA: F=210.65, P<0.01). However, EPCA-2 levels in the prostate cancers with different pathological grade were no significant difference. Furthermore, for detection of prostate cancer, EPCA-2 had a sensitivity of 81.9% and a specificity of 87.6%. CONCLUSIONS: Serum EPCA-2 could be used as a potential serological marker to diagnose prostate cancer in Chinese Han population, which was more specific than PSA and did not associate with pathological grades of prostate cancer.
BACKGROUND: Early prostate cancer antigen 2 (EPCA-2), a kind of nuclear matrix protein, may relate to prostate cancer. However, the association of EPCA-2 level in serum with prostate diseases has not been clarified in Chinese Han population. METHODS: EPCA-2 and prostate-specific antigen (PSA) levels in serum were detected by enzyme linked immunosorbent assay in 116 patients with prostate cancer (PCa), 342 patients with benign prostatic hyperplasia (BPH), and 174 healthy controls (Control) in Chinese population. Associations of serum EPCA-2 and PSA level with prostate diseases were analyzed by ANOVA. Comparison of diagnostic effect for prostate cancer between EPCA-2 and PSA was evaluated by Receiver Operator Curve, Chi-square test, and others. RESULTS: Serum EPCA-2 and PSA levels in PCa group were significantly higher than BPH and Control group (EPCA-2: F=200.05, P<0.01; PSA: F=210.65, P<0.01). However, EPCA-2 levels in the prostate cancers with different pathological grade were no significant difference. Furthermore, for detection of prostate cancer, EPCA-2 had a sensitivity of 81.9% and a specificity of 87.6%. CONCLUSIONS: Serum EPCA-2 could be used as a potential serological marker to diagnose prostate cancer in Chinese Han population, which was more specific than PSA and did not associate with pathological grades of prostate cancer.
Authors: Kevin T McVary; Claus G Roehrborn; Andrew L Avins; Michael J Barry; Reginald C Bruskewitz; Robert F Donnell; Harris E Foster; Chris M Gonzalez; Steven A Kaplan; David F Penson; James C Ulchaker; John T Wei Journal: J Urol Date: 2011-03-21 Impact factor: 7.450
Authors: Ali Saribacak; Hasan Yilmaz; Seyfettin Ciftci; Murat Ustuner; Levend Ozkan; Tayyar Alp Ozkan; Ozdal Dillioglugil Journal: Int J Clin Exp Med Date: 2014-08-15
Authors: Barbara Paul; Rajiv Dhir; Douglas Landsittel; Moira R Hitchens; Robert H Getzenberg Journal: Cancer Res Date: 2005-05-15 Impact factor: 12.701
Authors: Rajiv Dhir; Barbara Vietmeier; Julie Arlotti; Marie Acquafondata; Douglas Landsittel; Robert Masterson; Robert H Getzenberg Journal: J Urol Date: 2004-04 Impact factor: 7.450
Authors: Ian M Thompson; Donna K Pauler; Phyllis J Goodman; Catherine M Tangen; M Scott Lucia; Howard L Parnes; Lori M Minasian; Leslie G Ford; Scott M Lippman; E David Crawford; John J Crowley; Charles A Coltman Journal: N Engl J Med Date: 2004-05-27 Impact factor: 91.245